Open a free Demat account & get ₹500 in stocks.Claim
Nifty 5023,350.551.29%H 23,360.5 · L 23,211.8as of 12:17 PM IST|Sensex75,3631.21%H 75,557.06 · L 75,097.5as of 12:02 PM IST|Bank Nifty54,947.050.48%H 55,046.35 · L 54,701.9as of 12:17 PM IST|USD / INR₹94.890.05%H ₹94.95 · L ₹94.69as of 12:17 PM IST|Gold Intl (10g)₹1,19,493.230.45%H ₹1,19,825.78 · L ₹1,18,651.17as of 12:07 PM IST|Silver Intl (1kg)₹1,53,355.642.01%H ₹1,54,377.71 · L ₹1,49,770.78as of 12:07 PM IST|Crude WTI₹9,553.083.31%H ₹9,750.46 · L ₹9,506.58as of 12:07 PM IST|Bitcoin₹73,86,7810.41%H ₹74,02,002.6 · L ₹73,71,559.4as of 01 Nov, 5:48 PM IST|Ethereum₹2,14,4910.64%H ₹2,15,177.53 · L ₹2,13,804.47as of 01 Nov, 5:48 PM IST|Nifty 5023,350.551.29%H 23,360.5 · L 23,211.8as of 12:17 PM IST|Sensex75,3631.21%H 75,557.06 · L 75,097.5as of 12:02 PM IST|Bank Nifty54,947.050.48%H 55,046.35 · L 54,701.9as of 12:17 PM IST|USD / INR₹94.890.05%H ₹94.95 · L ₹94.69as of 12:17 PM IST|Gold Intl (10g)₹1,19,493.230.45%H ₹1,19,825.78 · L ₹1,18,651.17as of 12:07 PM IST|Silver Intl (1kg)₹1,53,355.642.01%H ₹1,54,377.71 · L ₹1,49,770.78as of 12:07 PM IST|Crude WTI₹9,553.083.31%H ₹9,750.46 · L ₹9,506.58as of 12:07 PM IST|Bitcoin₹73,86,7810.41%H ₹74,02,002.6 · L ₹73,71,559.4as of 01 Nov, 5:48 PM IST|Ethereum₹2,14,4910.64%H ₹2,15,177.53 · L ₹2,13,804.47as of 01 Nov, 5:48 PM IST|
0%
real-estateBreaking

Eli Lilly to Launch Four New Weight-Loss Drugs, Sees Potential in Indian Biotech Despite Funding Lag

Arth Vani DeskPublished: 1 min read
Eli Lilly to Launch Four New Weight-Loss Drugs, Sees Potential in Indian Biotech Despite Funding Lag

Source: ET Real Estate

Arth Insight · What this means for your wallet

Immediate action
Research promising Indian pharmaceutical and biotech companies.
  • New weight-loss treatments from Eli Lilly, if launched in India, could offer new health solutions but may come with significant costs (₹).
  • Eli Lilly's interest in Indian biotech could boost related Indian pharma/biotech stocks, potentially creating investment opportunities.
  • Potential foreign partnerships could lead to job creation and economic growth in India's biotech sector, indirectly benefiting the economy.
Recommended for you
Check home-loan rates & eligibility
Explore Home Loans
Listen to this article
AI voice · Podcast mode
Get IPO & market alerts free on Telegram / WhatsApp
AI Summary

Pharmaceutical giant Eli Lilly, driven by the success of Mounjaro and Zepbound, aims to launch up to four new weight-loss products in the coming years. The company acknowledges India's strong biotechnology talent and expertise, but highlights existing challenges in the research funding environment. Eli Lilly has expressed openness to forming partnerships with Indian biotech firms for future collaborations.

Key Highlights
  • ▸Eli Lilly plans to launch up to four new weight-loss products globally, building on the success of Mounjaro and Zepbound.
  • ▸The pharmaceutical giant recognizes India's strong talent and expertise in the biotechnology sector.
  • ▸A significant hurdle for India's biotech industry is the insufficient research funding ecosystem.
  • ▸Eli Lilly is actively seeking partnerships with Indian biotechnology firms to foster future collaborations.
Key Takeaways
  • ✓Eli Lilly plans to launch up to four new weight-loss products globally, building on the success of Mounjaro and Zepbound.
  • ✓The pharmaceutical giant recognizes India's strong talent and expertise in the biotechnology sector.
  • ✓A significant hurdle for India's biotech industry is the insufficient research funding ecosystem.
  • ✓Eli Lilly is actively seeking partnerships with Indian biotechnology firms to foster future collaborations.

Global pharmaceutical major Eli Lilly is gearing up to introduce as many as four new weight-loss products in the coming years, capitalizing on the immense success of its existing medications, Mounjaro and Zepbound. These blockbuster drugs have significantly boosted the company's sales figures and market valuation, solidifying its position in the rapidly expanding weight-loss treatment market.

While innovating globally, Eli Lilly has also turned its attention towards India, identifying substantial potential within the nation's burgeoning biotechnology sector. The company's CEO acknowledged India's deep pool of talent and considerable scientific know-how, signaling a positive outlook on the country's capabilities in biotech research and development.

India's Biotech Potential vs. Funding Hurdles

Despite recognizing India's inherent strengths, Eli Lilly has pointed out a critical impediment: the lagging research funding ecosystem. This gap in adequate financial support for biotech research and development could potentially hinder the pace of innovation and the scaling of promising ventures within the country.

However, the pharmaceutical giant remains optimistic about collaborative opportunities. Eli Lilly has indicated its willingness to explore and forge partnerships with Indian biotechnology firms. Such collaborations could be instrumental in leveraging India's scientific expertise while potentially bridging some of the funding shortfalls through foreign investment and joint development initiatives.

The success of weight-loss drugs like Mounjaro and Zepbound has transformed the pharmaceutical landscape, creating a new frontier for innovation and investment. Eli Lilly's strategy to expand its product portfolio underscores the growing demand for effective treatments in this category. Its interest in India suggests a recognition of the country's role as a potential hub for future biotech advancements, provided the necessary support infrastructure, particularly in funding, can be strengthened.

For Indian retail readers, this development highlights the potential for growth and innovation within India's biotechnology and pharmaceutical sectors. While direct financial figures in INR are not available from the source, the overarching sentiment points to a sector ripe for development and partnerships, potentially leading to job creation and economic growth in the long run. Investors tracking the global pharma and biotech space may view this as an indicator of future opportunities in firms that align with such global giants.

This report is for informational purposes only and should not be considered investment advice.

Recommended for you
Products related to this story — compare & act
Smart picks
Nippon India Small Cap Fund
Nippon India Mutual Fund · Small Cap
12.9%
3Y CAGR
Parag Parikh Flexi Cap Fund
PPFAS Mutual Fund · Flexi Cap
12.4%
3Y CAGR
Mirae Asset ELSS Tax Saver Fund
Mirae Asset Mutual Fund · ELSS
11.9%
3Y CAGR
Axis ELSS- Tax Saver Fund
Axis Mutual Fund · ELSS
10.7%
3Y CAGR
ICICI Prudential Balanced Advantage Fund
ICICI Prudential Mutual Fund · Hybrid
10.6%
3Y CAGR
HDFC Balanced Advantage Fund
HDFC Mutual Fund · Hybrid
10.5%
3Y CAGR

Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.

Frequently Asked Questions

What are Eli Lilly's plans for the weight-loss market?

Eli Lilly plans to launch up to four new weight-loss products in the coming years, continuing its expansion after the success of Mounjaro and Zepbound.

How does Eli Lilly view India's biotechnology sector?

The company sees significant potential in India's biotech talent and know-how, but notes that the research funding environment lags behind.

Is Eli Lilly open to partnerships with Indian firms?

Yes, Eli Lilly is actively open to forming collaborations with Indian biotechnology firms for future projects.

Stay ahead of the market

Join the Arth Vani channels

Daily news summaries, IPO & market alerts on Telegram and WhatsApp.

Related Stories

Piramal Pharma Slashes China Reliance to Under 10% for Supply Chain Resilience
Breaking
real-estate

Piramal Pharma Slashes China Reliance to Under 10% for Supply Chain Resilience

Piramal Pharma has significantly reduced its dependence on Chinese raw materials to less than 10%. This strategic move aims to enhance supply chain resilience against geopolitical risks, with the company expanding its manufacturing footprint to India, the UK, and the US.

4d ago·1 min readListen
Dr Reddy's Pivots to Generic Semaglutide, Biosimilars for Future Growth
real-estate

Dr Reddy's Pivots to Generic Semaglutide, Biosimilars for Future Growth

Dr Reddy's Laboratories is strategically focusing on the relaunch of generic semaglutide and expanding its biosimilars portfolio to drive future growth. This comes as the company navigates mixed results, with domestic formulations business growing but North American Revlimid sales declining in the September quarter.

7d ago·2 min readListen
Aayush Wellness Launches Calcium & Vitamin D Tablets, Enters ₹1.35 Lakh Crore Bone Health Market
real-estate

Aayush Wellness Launches Calcium & Vitamin D Tablets, Enters ₹1.35 Lakh Crore Bone Health Market

Aayush Wellness Limited has launched new calcium and vitamin D tablets, marking its entry into India's significant bone and joint health segment. This expansion reflects the growing consumer demand for preventive healthcare and nutritional supplements designed to support musculoskeletal health.

15d ago·1 min readListen
NITI Aayog Eyes Policy Reforms to Boost India's Medical Device Manufacturing
real-estate

NITI Aayog Eyes Policy Reforms to Boost India's Medical Device Manufacturing

NITI Aayog is actively exploring new policy measures to enhance India's domestic manufacturing capabilities for medical and dental devices. The initiative addresses significant hurdles like complex regulations and cost disadvantages faced by local producers. The goal is to strengthen the 'Make in India' drive within the crucial healthcare sector.

16d ago·2 min readListen